Advancing COPD treatment strategies with evidencebased. 17:15 19:15 Monday 11 September 2017 ERS 2017, Milan, Italy
|
|
- Meredith Lewis
- 5 years ago
- Views:
Transcription
1 Advancing COPD treatment strategies with evidencebased approaches 17:15 19:15 Monday 11 September 2017 ERS 2017, Milan, Italy
2 Increasing understanding of COPD and the effect on guideline evolution. GOLD 2017: the what, the why and the how Nicolas Roche, Respiratory and Intensive Care Medicine Cochin Hospital, AP-HP University Paris Descartes, France September 2017 GLRESP/COPD/0246m Novartis Pharma AG
3 Disclosures Activity Board membership Consultancy Grants and unrestricted funding for investigator-initiated studies Lectures Manuscript preparation Development of educational materials Travel/accommodation/meeting registration Mundipharma Novartis Pfizer Sandoz Sanofi Teva Zambon Company Mundipharma, Boehringer Ingelheim, TEVA, Pfizer, Novartis 3M, Sanofi, Sandoz, GSK Boehringer Ingelheim, Pfizer, Novartis Boehringer Ingelheim, Novartis, AstraZeneca, GSK, Chiesi, Cipla, Pfizer Novartis, AstraZeneca Zambon Boehringer Ingelheim, Novartis, AstraZeneca, GSK, Chiesi GOLD Science Committee
4 A historical perspective focused on treatment indications
5 As a preamble: old and new GOLD COPD definition GOLD < Chronic Obstructive Pulmonary Disease (COPD), a common preventable and treatable disease that is: characterized by persistent airflow limitation usually progressive associated with an enhanced chronic inflammatory response to noxious particles or gases in the airways and the lung GOLD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease that is: characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases 1. GOLD Available from: 2. GOLD Available from:
6 Back to basics: goals of COPD management Symptoms Reduce symptoms Exercise tolerance Health status Reduce risk Progression Exacerbations Mortality GOLD
7 Available medications (2001) Short-acting bronchodilators LABA ICS monotherapy was available, but indicated in very few countries for COPD Theophylline Mucoactive agents* *Not indicated for the long-term treatment of COPD ICS = inhaled corticosteroids; LABA = long-acting b 2 agonist
8 GOLD (2001) FVC = forced vital capacity; FEV 1 = forced expiratory volume in 1 second Pauwels RA, et al. Am J Respir Crit Care Med 2001;163:
9 GOLD (2007) Severity (all: FEV 1 /FVC <0.7) I: mild FEV 1 : >80% II: moderate FEV 1 : 50/60 80% III: severe FEV 1 : 30 50/60% IV: very severe FEV 1 <30% Risk factors avoidance; vaccines + prn short-acting bronchodilator + regular long-acting bronchodilator(s) + rehabilitation + fixed ICS-LABA combination if repeated exacerbations Roflumilast if CB + exacerbations ± LTOT surgery CB = chronic bronchitis; LTOT = long-term oxygen therapy ; prn = pro re nata (as needed) Rabe KF, et al. Am J Respir Crit Care Med 2007;176:532 55
10 Available medications (2017) Short-acting bronchodilators LABA LAMA LAMA+ICS In most countries, ICS are not indicated outside of fixed dose combinations LABA+LAMA LABA+ICS LAMA+LABA+ICS Theophylline Mucoactive agents* Roflumilast Macrolides* *Not indicated for the-long term treatment of COPD GOLD Available from:
11 A benefit-risk approach to treatment recommendations Individual presentation and underlying mechanisms Individual risk factors and comorbidities Expected Benefits Individualizing treatment choices in COPD Current COPD pharmacological treatments Expected Risks ALSO CONSIDER COSTS AND PREFERENCES Woodruff PG, et al. Lancet 2015;385:
12 GOLD (2011) GOLD 4 GOLD 3 C ICS/LABA or LAMA D ICS/LABA and/or LAMA 2 or more exacerbations/ year GOLD 2 GOLD 1 A SABA or SAMA prn B LABA or LAMA Less than 2 exacerbations/ year mmrc 0 1 CAT <10 mmrc 2 CAT 10 CAT = COPD Assessment Test; mmrc = modified Medical Research Council dyspnea scale Vestbo J, et al. Am J Respir Crit Care Med 2013;187:347 65
13 GOLD C and D patients were not the same! % of the population Exacerbations/year C1 (FEV 1 ) 4% 0.58 C2 (exacerbations) 1% 0.55 C3 (both) <1% 1.39 D1 (FEV 1 ) 26% 0.89 D2 (exacerbations) 6% 1.34 D3 (both) 9% 1.86 N=4,484 Han MK, et al. Lancet Respir Med 2013;1:43 50
14 GOLD 2017: the refined ABCD assessment tool Risk (GOLD classification of airflow limitation, FEV 1 % pred) Risk (exacerbation history in previous year) Exacerbation history 4 (<30) 3 (30 49) C D 2 or 1 leading to hospital admission 2 or 1 leading to hospital admission C D 2 (50 79) 1 ( 80) A B CAT <10 CAT 10 Symptoms mmrc 0 1 mmrc 2 Breathlessness 0 or 1 (not leading to hospital admission) 0 or 1 (not leading to hospital admission) A mmrc 0 1 CAT < 10 Symptoms B mmrc 2 CAT 10 CCQ = clinical COPD questionnaire 1. GOLD Available from: 2. GOLD Available from: ( 2017 Global Strategy for Diagnosis, Management and Prevention of COPD all rights reserved. Use is by express license from the owner)
15 Don t forget that COPD care begins with spirometry! Spirometrically confirmed diagnosis ROLES OF SPIROMETRY: Diagnosis FEV 1 (% predicted) Assessment of severity of airflow obstruction (prognosis) Post-bronchodilator GOLD 1 80 Follow-up FEV 1 /FVC assessment <0.7 GOLD Therapeutic decisions: - pharmacological changes - consideration of alternative diagnoses Assessment of airflow limitation GOLD GOLD 4 <30 - non-pharmacological treatments (e.g. interventional) Identification of rapid decline Exacerbation history 2 or 1 leading to hospital admission 0 or 1 (not leading to hospital admission) Assessment of symptoms/risk of exacerbations C A mmrc 0 1 CAT < 10 Symptoms D B mmrc 2 CAT Global Strategy for Diagnosis, Management and Prevention of COPD all rights reserved. Use is by express license from the owner. Available from:
16 GOLD 2017: new pharmacological treatment recommendations Group C Group D LAMA+LABA LABA+ICS Consider roflumilast if FEV 1 <50% pred. and patient has chronic bronchitis Consider macrolide (in former smokers) Further exacerbation(s) LAMA Further exacerbation(s) Further exacerbation(s) LAMA LAMA+LABA +ICS LAMA+LABA Persistent symptoms/further exacerbations LABA+ICS Group A Group B Continue, stop or try alternative class of bronchodilator LAMA+LABA Evaluate effect Persistent symptoms Preferred treatment A bronchodilator A long-acting bronchodilator (LABA or LAMA) 2017 Global Strategy for Diagnosis, Management and Prevention of COPD all rights reserved. Use is by express license from the owner. Available from:
17 GOLD A therapeutic recommendations Group A Continue, stop or try alternative class of bronchodilator Evaluate effect A bronchodilator 2017 Global Strategy for Diagnosis, Management and Prevention of COPD all rights reserved. Use is by express license from the owner). Available from:
18 GOLD B therapeutic recommendations Group B LAMA+LABA Persistent symptoms A long-acting bronchodilator (LABA or LAMA) 2017 Global Strategy for Diagnosis, Management and Prevention of COPD all rights reserved. Use is by express license from the owner). Available from:
19 GOLD C therapeutic recommendations Group C LAMA+LABA LABA+ICS Further exacerbation(s) LAMA 2017 Global Strategy for Diagnosis, Management and Prevention of COPD all rights reserved. Use is by express license from the owner). Available from:
20 GOLD D therapeutic recommendations Group D Consider roflumilast if FEV 1 <50% pred. and patient has chronic bronchitis Consider macrolide (in former smokers) Further Exacerbation(s) Further Exacerbation(s) LAMA+LABA+ICS Persistent symptoms/further exacerbations Until 2016: exacerbations ICS 2017 onwards: 1st line = long-acting bronchodilator(s) LAMA LAMA+LABA LABA+ICS 2017 Global Strategy for Diagnosis, Management and Prevention of COPD all rights reserved. Use is by express license from the owner). Available from:
21 What about triple therapy? What we know: triple vs: Placebo LAMA (added value of LABA+ICS) LABA+ICS (added value of the LAMA) What we don t have: triple vs LABA+LAMA Added value of the ICS Clinicaltrials.gov IMPACT: triple vs LABA+LAMA vs LABA+ICS 1 TRIBUTE: triple vs LABA+LAMA 2 ETHOS: triple vs LABA+LAMA vs LABA+ICS 3 SUNSET: triple vs LABA+LAMA 4 1. ClinicalTrials.gov. NCT ClinicalTrials.gov. NCT ClinicalTrials.gov. NCT ClinicalTrials.gov. NCT
22 Personalizing pharmacological therapy for COPD
23 COPD endotypes for personalized/precision medicine Biomarker-directed personalized medicines approaches Endotypes COPD with persistent systemic inflammation Eosinophilic or Th2 high COPD Endotype COPD with persistent pathogenic bacterial colonization Infection (variable) Exposome Inflammation (variable) Cellular and matrix changes Extracellular matrix destruction; abnormal cell repair or apoptosis; ciliary dysfunction, mucus Endotype α-1 antitrypsin deficiency Structural changes Airways remodeling; alveolar destruction Biomarker-directed personalized medicines approaches Genetics Physiological dysfunction Clinical manifestations of COPD Woodruff PG, et al. Lancet. 2015;385:
24 The Blood Eosinophil Debate 4 studies/analyses ICS/LABA vs LABA or LABA/LAMA - SFC vs salmeterol 1 - FF/VI vs VI 2,3 - BDP/FOR vs FOR 4 - SFC+Tio vs Tio+salmeterol 5,6 BUT ICS vs no ICS - FP vs placebo 7 ICS/LABA vs LABA/LAMA - SFC vs IND/GLY 8 Blood eosinophils identify patients in whom ICS + long-acting bronchodilator(s) are superior to long-acting bronchodilator(s) alone Contradictory evidence BDP = beclomethasone dipropionate; IND/GLY=indacaterol/glycopyrronium; TIO = tiotropium 1. Pavord ID, et al. Thorax 2016;71:118 25; 2. Pascoe S, et al. Lancet Respir Med 2015;3:435 42; 3. Hinds DR, et al. BMJ Open 2016;6:e010099; 4. Siddiqui SH, et al. Am J Respir Crit Care Med 2015; 192:523 25; 5. Calverley PMA, et al. Am J Respir Crit Care Med 2017 [Epub ahead of print]; 6. Watz H, et al. Lancet Respir Med 2016;4:390 8; 7. Barnes NC, et al. Eur Respir J 2016;47: Roche N, et al. Am J Respir Crit Care Med 2017;195: ;
25 What about ACO? WARNING! Many ACO sub-phenotypes 1 Don t put all patients in the «ACO basket»! 2 Don t forget to think: differential diagnosis is essential GINA = Global Initiative for Asthma 1. Diagnosis of Diseases of Chronic Airflow Limitation: Asthma, COPD and Asthma-COPD Overlap Syndrome (ACOS) GINA. Global strategy for asthma management and prevention Available from:
26 When should phenotyping occur?
27 COPD: Official diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological Society Risk elimination (U)-LAMA ± (U)-LABA REHAB Mandatory treatment ICS/LABA Roflumilast BLVR/LVRS AAT ABT Mucoactive Rx Phenotypic treatment LTOT HOME NIV LuTX Palliative care Respiratory failure Rx and terminal care Smoking cessation Elimination of other Risks Regular walking Vaccination Checking inhaler technique AAT = alpha 1-antitrypsin; ABT= antibiotic therapy; BLVR = bronchoscopic lung volume reduction; LuTX = lung transplantation; LVRS = lung volume reduction surgery; NIV = non-invasive ventilation; rehab = rehabilitation Koblizek V, et al. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2013;157:
28 Inhaled therapy for COPD: don t forget the patient! PROBLEM : Preference Abilities Technique The ideal inhaler Do Treatment not effectiveness exist! Adherence The ideal healthcare professional The ideal patient GOLD
29 Overall, no improvement in inhaler technique over time! Sanchis J, et al. Chest 2016;150:
30 Device handling errors are common 212 GPs and 50 pulmonologists assessed the handling of 3,993 devices used for continuous treatment of COPD in 2,935 patients Device A B C D E F Total # Devices, n ,393 No error 36.5 ( ) 29.2 ( ) 10.7 ( ) 16.4 ( ) 23.0 ( ) 30.5 ( ) 25.3 ( ) Deviceindependent errors 53.5 ( ) 50.9 ( ) 54.8 ( ) 53.8 ( ) 56.8 ( ) 51.9 ( ) 53.8 ( ) Device-dependent errors 15.4 ( ) 29.2 ( ) 75.3 ( ) 70.1 ( ) 50.6 ( ) 32.1 ( ) 43.1 ( ) At least one critical error 15.4 ( ) 21.2 ( ) 29.3 ( ) 43.8 ( ) 46.9 ( ) 32.1 ( ) 30.0 ( ) *Errors were considered critical if they could have substantially affected dose delivery to the lungs; # total number of evaluated devices Adapted from Molimard M, et al. Eur Respir J 2017;49(2)
31 Conclusions The past: few available treatments, pessimistic view of their effects The present: hierarchized treatment options with demonstrated efficacy The future: tools for personalized care The what: personalized medicine for COPD The why: increasing understanding of treatment effects and their determinants The how: possible yield of biomarkers
Potential risks of ICS use
Potential risks of ICS use Randomised controlled trial Observational study Systematic review Pneumonia Tuberculosis Bone fracture Skin thinning/easy bruising Cataract Diabetes No effect on fracture risk
More informationWhat s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university
What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university Management stable COPD Relieve symptoms Improve exercise tolerance Improve health status Prevent
More informationCurriculum Vitae. Head of Public Wing HCU - RSCM. Head of ICU Sari Asih Ciledug Hospital
Curriculum Vitae Name : Dr. Ceva W. Pitoyo,SpPD,K-P,KIC,FINASIM POB / DOB : Jakarta, March 8th 1968 Education : o General Practitioner : FKUI 1993 o Internist : FKUI 2002 o Pulmonology Consultant : PAPDI-UI
More informationTHE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable
THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. COPD in the United States Third leading cause
More informationChanging Landscapes in COPD New Zealand Respiratory Conference
Changing Landscapes in COPD New Zealand Respiratory Conference Dr Robert Young BMedSc MBChB DPhil (Oxon) FRACP FRCP Associate Professor Consultant Physician Changing Landscapes in COPD: Summary 1. Overview
More informationDisclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:
Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict
More informationDefining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist
Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease
More informationCOPD GOLD Guidelines & Barnet inhaler choices. Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust
COPD GOLD Guidelines & Barnet inhaler choices Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust GOLD 2017 Report: Chapters 1. Definition and Overview 2. Diagnosis and Initial
More informationNuovi farmaci in sviluppo per la BPCO
PNEUMOLOGIA 2018 MILANO, 14 16 GIUGNO 2018 CENTRO CONGRESSI PALAZZO DELLE STELLINE Nuovi farmaci in sviluppo per la BPCO Leonardo M. Fabbri, MD, FERS Professor of Respiratory and Internal Medicine, University
More information2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters
GOLD Objectives To provide a non biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD. To highlight short term and long term treatment objectives organized
More informationTurning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital
Turning Science into Real Life Roflumilast in Clinical Practice Roland Buhl Pulmonary Department Mainz University Hospital Therapy at each stage of COPD I: Mild II: Moderate III: Severe IV: Very severe
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationOPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING 10/16/2018 DISCLOSURES I have no financial or other disclosures
OPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING J. Michael Fuller, MD, MEd, FACP, FCCP Associate Professor of Medicine University of South Carolina Greenville DISCLOSURES I have no financial or other
More informationCOPD: A Renewed Focus. Disclosures
COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss
More informationรศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น
รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น COPD Guideline Changing concept in COPD management Evidences that we can offer COPD patients better life COPD Guidelines
More informationAdvances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015
Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Chronic obstructive pulmonary disease (COPD) COPD in Hong
More informationCOPD: Current Medical Therapy
COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for
More information2017 GOLD Report. Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017
2017 GOLD Report Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017 Lauren Munro; BSc(Pharm) Amanda Burns; BSc(Pharm) Pharmacy Residents The Moncton Hospital Objectives Explain
More informationTreatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark
Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD)
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) Zahava Picado, PharmD PGY1 Pharmacy Practice Resident Central Texas Veterans Healthcare System Temple, TX October
More information11/27/18. Challenges in Pulmonary and Critical Care: COPD So Much is New! Faculty. Disclosures
Challenges in Pulmonary and Critical Care: 2018 COPD So Much is New! 1 Faculty Anas Hadeh, MD, FCCP Director, Pulmonary and Critical Care Medicine Fellowship Program Affiliate Assistant Professor of Clinical
More informationCOPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health
COPD: Treatment Update Barry Make, MD Professor of Medicine National Jewish Health Disclosures Advisory board, consultant, multi-center trial, research funding, Data Safety Monitoring Board (DSMB), or
More informationCOPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms
COPD: Preventable and Treatable Christopher H. Fanta, M.D. Partners Asthma Center Pulmonary and Critical Care Division Brigham and Women s Hospital Harvard Medical School Lecture Outline I. Diagnosis and
More informationConfronting the Challenges of COPD. What is New in The Approaches to Diagnosis, Treatment, and Patient Outcomes
Confronting the Challenges of COPD What is New in The Approaches to Diagnosis, Treatment, and Patient Outcomes COPD Definition GOLD: Global Initiative for Chronic Obstructive Lung Disease Common, preventable,
More informationCOPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis.
1 Definition of COPD: COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis. Airflow obstruction may be accompanied by airway hyper-responsiveness
More informationDr Stephen Child. General Physician Auckland. 14:20-14:40 Secondary Care Perspective
Dr Stephen Child General Physician Auckland 14:20-14:40 Secondary Care Perspective Wheeze Witchery Stephen Child MD, FRACP, FRCPC General Physician Respiratory Interest Director of Clinical Training Auckland
More informationUPDATE ON GOLD GUIDELINES IN COPD
UPDATE ON GOLD GUIDELINES IN COPD GERARD J. CRINER, MD, FACP, FACCP PROFESSOR, THORACIC MEDICINE & SURGERY TEMPLE UNIVERSITY SCHOOL OF MEDICINE PHILADELPHIA, PA Gerard J. Criner, MD, is Professor and Founding
More informationUp in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018
Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize
More informationChronic obstructive pulmonary disease
0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find
More informationCOPD: GOLD guidelines Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS
COPD: GOLD guidelines 2017 Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS Introduction The Global Initiative for Chronic Obstructive Lung Disease (GOLD) program was
More informationUpdate on heterogeneity of COPD, evaluation of COPD severity and exacerbation
Update on heterogeneity of COPD, evaluation of COPD severity and exacerbation Yung-Yang Liu, MD Taipei Veterans General Hospital Aug 29, 2015 G O lobal Initiative for Chronic bstructive L D ung isease
More informationGuideline for the Diagnosis and Management of COPD
Guideline for the Diagnosis and Management of COPD Introduction Chronic obstructive pulmonary disease (COPD) is a respiratory disorder largely caused by smoking. It is characterized by progressive, partially
More informationCOPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor
COPD Update Plus New and Improved Products for Inhaled Therapy Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose concerning possible financial
More informationChronic Obstructive Pulmonary Disease: What s New in Therapeutic Management?
Chronic Obstructive Pulmonary Disease: What s New in Therapeutic Management? Sabrina Sherwood, PharmD PGY2 Internal Medicine Resident University of Utah Health September 29, 2018 Disclosures Relevant disclosures
More informationJOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES
JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES Authors Dr Ian Benton Respiratory Consultant COCH Penny Rideal Respiratory Nurse COCH Kirti Burgul Respiratory Pharmacist COCH Pam
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) October 26 th, 2018 Zahava Picado, PharmD PGY1 Pharmacy Resident Central Texas Veterans Healthcare System Zahava.Picado@va.gov
More informationIf you require this document in another format such as Braille, large print, audio or another language please contact the Trusts Communications Team
MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN ADULTS Summary statement: How does the document support patient care? Staff/stakeholders involved in development: Job titles only Division:
More informationPharmacotherapy for COPD
10/3/2017 Topics to be covered Pharmacotherapy for chronic treatment Pharmacotherapy for COPD Dr. W C Yu 3rd September 2017 Commonly used drugs Guidelines for their use Inhaled corticosteroids (ICS) in
More informationASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?
ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? Randall W. Brown, MD MPH AE-C Association of Asthma Educators Annual Conference July 20, 2018 Phoenix, Arizona FACULTY/DISCLOSURES Randall Brown,
More informationAsthma COPD Overlap (ACO)
Asthma COPD Overlap (ACO) Dr Thomas Brown Consultant Respiratory Physician Thomas.Brown@porthosp.nhs.uk Dr Hitasha Rupani Consultant Respiratory Physician Hitasha.rupani@porthosp.nhs.uk What is Asthma
More informationPFT s / 2017 Pulmonary Update. Eric S. Papierniak, DO University of Florida NF/SG VHA
PFT s / 2017 Pulmonary Update Eric S. Papierniak, DO University of Florida NF/SG VHA Outline Overview of pulmonary function testing Uses/indications/limitations Technical aspects Basics of interpretation
More informationObjectives. Advances in Managing COPD Patients
4:45 5:30pm Advances in Managing Patients SPEAKER Nicola Hanania, MD, FCCP, FRCP, FACP Presenter Disclosure Information The following relationships exist related to this presentation: Nicola Hanania, MD,
More informationCOPD: From Phenotypes to Endotypes. MeiLan K Han, M.D., M.S. Associate Professor of Medicine University of Michigan, Ann Arbor, MI
COPD: From Phenotypes to Endotypes MeiLan K Han, M.D., M.S. Associate Professor of Medicine University of Michigan, Ann Arbor, MI Presenter Disclosures MeiLan K. Han Consulting Research support Novartis
More informationGOLD 2017: cosa c è di nuovo
GOLD 2017: cosa c è di nuovo Antonio Spanevello Università degli Studi dell Insubria, Varese Dipartimento di Medicina e Chirurgia Istituti Clinici Scientifici Maugeri, IRCCS, Tradate Dipartimento di Medicina
More informationFact. Objectives 1/6/2016. Reducing Hospital Readmissions for Chronic Obstructive Pulmonary Disease (COPD)
Reducing Hospital Readmissions for Chronic Obstructive Pulmonary Disease (COPD) Jin S. Oh, PharmD Larkin Community Hospital January 10, 2016 Fact COPD is the third leading cause of death in the United
More information#POMAD8 #ChoosePOMA #POMAD8 #ChoosePOMA #POMAD8 #ChoosePOMA
Where There s Smoke There s Obstruction Stephen G. Basheda, D.O., F.C.C.P. 1 Disclosures Dr. Basheda is an independent contractor for AstraZeneca Pharmaceuticals, LP and GlaxoSmithKline and on the speaker
More informationAsma e BPCO: le strategie terapeutiche
Asma e BPCO: le strategie terapeutiche Dott. Marco Contoli ctm@unife.it Sezione di Medicina Interna e Cardio-Respiratoria Dipartimento di Scienze Mediche Università di Ferrara COPD Definition Chronic Obstructive
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationThe Journal Club: COPD Exacerbations
252 The Journal Club: COPD Exacerbations Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation Journal Club The Journal Club: COPD Exacerbations Ron Balkissoon, MD, MSc, DIH, FRCPC 1 Abbreviations:
More informationTitle: Real-life use of inhaled corticosteroids in COPD patients vs. GOLD proposals: a paradigm shift in GOLD 2011?
ERJ Express. Published on October 31, 2013 as doi: 10.1183/09031936.00162313 Letter to the Editor Title: Real-life use of inhaled corticosteroids in COPD patients vs. GOLD proposals: a paradigm shift in
More informationRoflumilast (Daxas) for chronic obstructive pulmonary disease
Roflumilast (Daxas) for chronic obstructive pulmonary disease August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationGOLD UPDATE on COPD and the Importance of Accurate Dyspnea Evaluation
GOLD UPDATE on COPD and the Importance of Accurate Dyspnea Evaluation George Anderson, PhD Sr. Medical Science Liaison MA-AZAP ML-4006-US-0212 Approved 11/16 Glob al Strategy for the Diagnosis, Management,
More informationCARE OF THE ADULT COPD PATIENT
CARE OF THE ADULT COPD PATIENT Target Audience: The target audience for this clinical guideline is all MultiCare providers and staff including those associated with our Clinically Integrated Network. The
More informationWINDY CITY WHEEZE: A PREVENTATIVE APPROACH TO COPD MANAGEMENT
WINDY CITY WHEEZE: A PREVENTATIVE APPROACH TO COPD MANAGEMENT Thursday, October 25, 2018 Sarah Sungurlu DO Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures I have no actual
More informationSABA: VENTOLIN EVOHALER (SALBUTAMOL) SAMA: ATROVENT IPRATROPIUM. Offer LAMA (discontinue SAMA) OR LABA
COPD GUIDELINES DIAGNOSIS >35 years of age Symptoms of cough, breathlessness, sputum, wheeze, Risk factor (SMOKING) Spirometry (post bronchodilator) FEV1/FVC = 0.7 ENCOURAGE PATIENTS TO BRING INHALERS
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma
More informationTo describe the impact of COPD exacerbations and the importance of the frequent exacerbator phenotype.
Educational aims To describe the impact of COPD exacerbations and the importance of the frequent exacerbator phenotype. To describe the spectrum of pharmacological and non-pharmacological interventions
More informationCOPD exacerbation. Chiara Maruggi, PGY2
COPD exacerbation Chiara Maruggi, PGY2 Learning objectives At the end of this lecture students will be able to: 1) Critically assess patients for COPD and design a management plan. 2) Develop a step-wise
More informationGlobal Initiative for Chronic Obstructive Lung Disease
Global Initiative for Chronic Obstructive Lung Disease POCKET GUIDE TO COPD DIAGNOSIS, MANAGEMENT, AND PREVENTION A Guide for Health Care Professionals 2019 REPORT GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE
More informationChronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC
Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC I have no financial disclosures Definition COPD is a preventable and treatable disease
More informationDisclosures. Update on COPD & Asthma. Update on the Management of COPD. No Pharma Disclosures. NHLBI - Asthma Clinical Research Network
Update on COPD & Asthma Michael C. Peters, M.D. MAS Division of Pulmonary & Critical Care Medicine Cardiovascular Research Institute University of California San Francisco UCSF Primary Care Medicine San
More informationCOPD EXACERBATIONS AND HOSPITAL ADMISSIONS HOW CAN WE PREVENT THEM? Wisia Wedzicha National Heart and Lung Institute, Imperial College London, UK
COPD EXACERBATIONS AND HOSPITAL ADMISSIONS HOW CAN WE PREVENT THEM? Wisia Wedzicha National Heart and Lung Institute, Imperial College London, UK Presenter Disclosures Wisia Wedzicha All disclosures prior
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationCurrent Approaches to Asthma & COPD
10/11/18 Current Approaches to Asthma & COPD Lekshmi Santhosh, M.D. Assistant Professor, Pulm/Critical Care & Hosp Med Primary Care Medicine: Principles & Practice 10.11.2018 Revisiting the Dutch Hypothesis:
More informationChanging Epidemiology: Quick Facts 9/28/2018. During the year New Treatment Options for COPD: Phenotypes, Endotypes or Treatable Traits?
New Treatment Options for COPD: Phenotypes, Endotypes or Treatable Traits? Conflict of Interest Statement 2018 Speakers Bureau Astra Zeneca Boehringer Ingelheim Genentech Sunovion Ron Balkissoon MD DIH
More informationOptimum treatment for chronic obstructive pulmonary disease exacerbation prevention
Commentary Page 1 of 5 Optimum treatment for chronic obstructive pulmonary disease exacerbation prevention Pradeep Karur, Dave Singh Centre for Respiratory Medicine and Allergy, Medicines Evaluation Unit,
More informationCOPD Therapeutic Update
COPD Therapeutic Update The first ever NT patient.. Hubertus PA Jersmann MBBS, MD, PhD, FRACP, FThorSoc, AMA(M) Professor, School of Medicine, University of Adelaide Respiratory and Sleep Physician, Royal
More informationCHRONIC OBSTRUCTIVE LUNG DISEASE (COPD), BRONCHIAL ASTHMA
CHRONIC OBSTRUCTIVE LUNG DISEASE (COPD), BRONCHIAL ASTHMA GOLD GINA Chronic Obstructive Pulmonary Disease (COPD) COPD is currently the fourth leading cause of death in the world.1 COPD is projected to
More informationBlue, Pink and everything in between: an update on COPD. Tara Lohmann MD FRCPC Division of Respirology University of Calgary
Blue, Pink and everything in between: an update on COPD Tara Lohmann MD FRCPC Division of Respirology University of Calgary Disclosures I have eaten lunches provided by many pharmaceutical companies (GSK,
More informationDisclosure Statement. Epidemiological Data
EVALUATION OF THE MEDICATION UTILIZATION OF COPD PATIENTS AT THE MIAMI VA HEALTHCARE SYSTEM Simone Edgerton, PharmD. PGY 1 Pharmacy Resident Miami VA Healthcare System Miami, Florida Simone.edgerton2@va.gov
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Chronic obstructive pulmonary disease: the management of adults with chronic obstructive pulmonary disease in primary and secondary
More informationCOPD and Asthma Update. April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute
COPD and Asthma Update April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute What we ll be talking about COPD: diagnosis, management of stable COPD, COPD exacerbations Asthma: diagnosis,
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Calverley P M A, Anzueto A R, Carter K, et
More informationAddressing Undertreatment
Objectives TOWARD BETTER COPD OUTCOMES The Critical Role of Primary Care for Early Diagnosis and Guideline-directed Management Keith Robinson, MD, MS, FCCP Pulmonary Physicians of South Florida, LLC Fusion
More informationCOPD. Salah Zeineldine, MD FACP Pulmonary & Critical Care Medicine American University of Beirut Lebanese Society of Family Medicine 2012
COPD Salah Zeineldine, MD FACP Pulmonary & Critical Care Medicine American University of Beirut Lebanese Society of Family Medicine 2012 Attitude It is a disease on which a good deal of wholly, unmerited
More informationChronic Obstructive Pulmonary Disease Guidelines and updates
Chronic Obstructive Pulmonary Disease Guidelines and updates October 20, 2018 Saratoga Springs, NY COPD (Chronic obstructive pulmonary disease) is a major cause of mortality and morbidity in the United
More informationThe Importance of Pulmonary Rehabilitation
November 21, 2017 The Importance of Pulmonary Rehabilitation Presenter: George Pyrgos, MD 1 The importance of Pulmonary Rehabilitation George Pyrgos, MD Medical Director of the Angelos Lung Center at Medstar
More informationCOPD. Breathing Made Easier
COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought
More informationAECOPD: Management and Prevention
Neil MacIntyre MD Duke University Medical Center Durham NC Professor P.J. Barnes, MD, National Heart and Lung Institute, London UK Professor Peter J. Barnes, MD National Heart and Lung Institute, London
More informationChoosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital
Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies
More informationWhat is COPD? COPD Pharmacotherapy. COPD Mortality Is Increasing
COPD Pharmacotherapy Chronic Bronchitis What is COPD? 75% 17.5% Emphysema Laura C. Feemster, MD, MS Assistant Professor University of Washington Division of Pulmonary & Critical Care April 23,2015 COPD
More informationManagement of COPD Updates and Evidence
Management of COPD Updates and Evidence Providence Alaska Medical Center PGY1 Pharmacy Practice Residents Ann-Chee Cheng, PharmD Kaite Kammers, PharmD http://www.fpnotebook.com/_media/lungxsgraybb962.gif
More informationCOPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013
COPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013 None Disclosures Definitions Asthma Asthma is a chronic inflammatory
More informationPharmacist Objectives. Pulmonary Update. Outline. Technician Objectives. GOLD Guidelines. COPD Diagnosis 9/22/2017
Pharmacist Objectives Pulmonary Update Patty Marshik, PharmD Associate Professor University of New Mexico College of Pharmacy pmarshik@salud.unm.edu Discuss the new Global Initiative for Chronic Obstructive
More informationHow to treat COPD? What is the mechanism of dyspnea? Smoking cessation
: The Increasing Role of the FP Alan Kaplan, MD, CCFP(EM) Presented at the Primary Care Today: Education Conference and Medical Exposition, Toronto, Ontario, May 2006. Chronic obstructive pulmonary disease
More informationLead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984]
Lead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984] 1 st Appraisal Committee meeting Background & Clinical Effectiveness John McMurray 11 th January 2016 For
More informationThe impacts of cognitive impairment on acute exacerbations of chronic obstructive pulmonary disease
The impacts of cognitive impairment on acute exacerbations of chronic obstructive pulmonary disease Dr. Lo Iek Long Department of Respiratory Medicine C.H.C.S.J. Chronic Obstructive Pulmonary Disease (COPD)
More informationChronic Obstructive Pulmonary Disease (COPD).
Chronic Obstructive Pulmonary Disease (COPD). Linde: Living healthcare 02 03 Chronic Obstructive Pulmonary Disease (COPD). A pocket guide for healthcare professionals. COPD the facts Moderate to severe
More informationAlgorithm for the use of inhaled therapies in COPD Version 2 May 2017
Algorithm for the use of inhaled therapies in COPD This document has been revised by the Berkshire West Respiratory Network to support clinicians in selecting the most appropriate, cost effective treatments
More informationCOPD/Asthma. Prudence Twigg, AGNP
COPD/Asthma Prudence Twigg, AGNP COPD/Asthma Qualifying Diagnosis Known diagnosis of COPD/asthma or CXR showing COPD with hyperinflated lungs and no infiltrates + two or more: Wheezing, SOB, increased
More informationBronchial Provocation Results: What Does It Mean?
Bronchial Provocation Results: What Does It Mean? Greg King 1 Department of Respiratory Medicine, Royal North Shore Hospital, St Leonards 2065 2 Woolcock Institute of Medical Research and Sydney Medical
More informationaclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationSyllabi/Slides for this program are a supplement to the live CME session and are not intended for other purposes.
10:50-11:50am Case Studies in Pulmonary Medicine for the Primary Care Clinician SPEAKERS Timothy J. Scialla, MD Common Shortcuts/Common Misperceptions Smoking + Dyspnea = COPD Hospitalization for cough
More informationPatient adherence to inhaled therapy A clinical perspective. Nicolas Roche Cochin, Site Val de Grâce University Paris Descartes, Paris, France
Patient adherence to inhaled therapy A clinical perspective Nicolas Roche Cochin, Site Val de Grâce University Paris Descartes, Paris, France 1 Disclosures Aerocrine Almirall AstraZeneca Boehringer Ingelheim
More informationAlgorithm for the use of inhaled therapies in COPD
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationDecramer 2014 a &b [21]
Buhl 2015 [19] Celli 2014 [20] Decramer 2014 a &b [21] D Urzo 2014 [22] Maleki-Yazdi 2014 [23] Inclusion criteria: Diagnosis of chronic obstructive pulmonary disease; 40 years of age or older; Relatively
More informationUPDATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
UPDATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE Radhika Shah, MD Erlanger Health System University of Tennessee College of Medicine Chattanooga Respiratory, Critical Care, and Sleep medicine No disclosures
More informationCOPD A New Look at an Old Disease
A New Look at an Old Disease Disclosures Research support to institution from Roche/Genentech, GSK, Astra Zeneca, Cheisi, Sunovion, Mylan, Boehringer Ingelheim Research support from the American Lung Association
More informationModern Management of COPD.
Modern Management of COPD. Associate Professor Robert Young BMedSc, MBChB, DPhil (Oxon), FRACP, FRCP Department of Medicine, Auckland City Hospital and University of Auckland, New Zealand 2 Sponsor Disclaimer
More informationCOPD Robert Schilz DO, PhD Pulmonary, Critical Care and Sleep Medicine University Hospitals Case Medical Center
COPD 2018 GOLD 2017 Report Global Initiative for Chronic Obstructive Lung D isease COPYRIGHTED MATERIAL- DO NOT COPY OR DISTRIBUTE GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF CHRONIC
More information